PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children

Abstract

Background/Objectives: Relapse or refractory brain tumor in childhood continue to have a dismal prognosis in spite of developing multidisciplinary treatment. Cancer immunotherapy is newly expected as next promising treatment for highly aggressive pediatric cancer. This trial was designed to evaluate the safety and clinical responses to an immunotherapy with fusions of dendritic cells (DCs) and tumor cells in patients with malignant brain tumors. Design/Methods: Patients with histopathologically confirmed high-grade or recurrent brain tumor were eligible for our immunotherapy. Autologous cultured tumor cells obtained from surgical specimens were fused with autologous DCs using polyethylene glycol. The fusion cells (FC) were inoculated intradermally in the cervical region and repeated 3–10 times in each 28–84 days cycle. Toxicity, progression-free survival (PFS), and overall survival (OS) of this trial were evaluated. Results: Six patients were enrolled, three with high grade glioma and three with ependymoma. Median age at first course of immunotherapy was 10 years (range 8–25 years) and median time of follow-up from first course of immunotherapy was 13.5 months (range 3–33 months). All patients with immunotherapy were well tolerated and no adverse event without local erythema in injected site. Median progression free survival and overall survival were 18 months and 18.5 months, respectively. Conclusions: FC immunotherapy with autologous DCs and tumor cells for brain tumor in children and young adults were extremely well tolerated and encouraging. Further phase II study of FC immunotherapy is planned to improve prognosis and overcome treatment related neurological sequelae for highly malignant tumors.